Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable Hepatocellular Carcinoma

NCT00635323 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00635323
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00635323 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Efficacy and Safety of Irinotecan (Campto®) in Combination With Capecitabine (Xeloda®) as First-Line Chemotherapy in Asian Subjects With Inoperable Hepatocellular Carcinoma
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2002
Completion date
May 31, 2005
Enrollment
73 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, hepatocellular